SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...

The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...

When dosing is optimized, biologics such as IFX are highly effective for managing CD and UC. Anser IFX testing uses a drug-tolerant homogeneous mobility shift assay (HMSA) to provide clinicians ...

The Prometheus Anser IFX test has been validated for use in patients with inflammatory bowel disease treated with Inflectra, the manufacturer announced. Inflectra (Celltrion) is the recently ...

The MarketWatch News Department was not involved in the creation of this content. New Therapeutic Drug Monitoring Test for Interleukin--23 Inhibitor SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / ...

Prometheus has announced the completion of the validation of its new monitoring test, Prometheus Anser VDZ, which measures both serum drug concentrations and antidrug antibody levels of vedolizumab in ...

The Prometheus Anser VDZ test has been validated for therapeutic drug monitoring in adults treated with Entyvio for inflammatory bowel disease, the company announced. The assay “uniquely measures both ...

Prometheus Laboratories announced the launch of Prometheus Anser ADA, a novel test to measure adalimumab (Humira; AbbVie) and its antibody levels in one serum sample for patients with inflammatory ...

SAN DIEGO, CA / ACCESSWIRE / August 1, 2023 / Prometheus Laboratories Inc. ("Prometheus") today announced a collaboration with Fresenius Kabi to support the validation of and access to Anser ® ...

SAN DIEGO, CA / ACCESS Newswire / August 27, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision healthcare, today announced a collaboration with Celltrion USA, Inc. ("Celltrion ...